RxDoctor Payments Data

Nathan Do, MD

Pulmonary Disease · Brandon, FLNPI 1649346230

Payments from drug & device makers

$18,433in general payments, 2019–2025

Across 717 payments — averaging $25.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • AstraZeneca$3K
  • GSK$2K
  • Actelion Pharmaceuticals US, Inc.$2K
  • Pulmonx Corporation$1K
  • Boehringer Ingelheim$609
  • plus $5K from 34 others

What the payments were for

  • Travel & lodging$2,18712%
  • Food & beverage$12,59668%
  • Education$3,65020%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,433 in reported general payments places this provider in the 75th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$297,003
Medicare patients
794
Services billed
3,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan80$1,006,247
UptraviSelexipag24$541,023
Trelegy ElliptaFluticasone/Umeclidin/Vilanter638$465,776
Orenitram ErTreprostinil Diolamine24$369,053
WinrevairSotatercept-Csrk18$366,293
OfevNintedanib Esylate24$311,671
TezspireTezepelumab-Ekko27$161,503
Breztri AerosphereBudesonide/Glycopyr/Formoterol174$151,424
AdempasRiociguat13$139,944
Dupixent PenDupilumab33$126,358
Dupixent SyringeDupilumab22$113,893
Ambrisentan36$86,166
Fasenra PenBenralizumab12$70,387
Breo ElliptaFluticasone/Vilanterol121$61,903
SymbicortBudesonide/Formoterol Fumarate109$32,845

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$1,776$1,547,271104 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$2,255$583,589899 claims
MerckWinrevair$321$366,29318 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$3,188$345,772310 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$609$337,02561 claims
PfizerEliquis$111$23,37730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →